NOVT:NASDAQNovanta Inc. analysis
Data as of May 19, 2026 - not real-time
- Latest price
- $151.27
- Risk: medium
- 7/10Medium risk
Summary
Novanta Inc. (NOVT) shows strong short‑term momentum. The 20‑day SMA sits comfortably above both the 50‑day and 200‑day SMAs, and the MACD line is crossing above its signal, confirming a bullish technical stance. RSI is in the mid‑60s, indicating continued buying pressure without being overbought. Recent earnings beat and accelerating bookings in automation and AI‑related infrastructure further support the upside, while volume is trending upward.
However, valuation metrics raise caution. The trailing PE is markedly higher than the industry average, and the DCF fair‑value estimate sits well below the current market price, implying limited upside from a fundamentals perspective. High beta and elevated 30‑day volatility suggest the stock could experience sizable swings, especially in broader market corrections. Investors should weigh the robust growth narrative against the premium valuation and heightened risk profile.
However, valuation metrics raise caution. The trailing PE is markedly higher than the industry average, and the DCF fair‑value estimate sits well below the current market price, implying limited upside from a fundamentals perspective. High beta and elevated 30‑day volatility suggest the stock could experience sizable swings, especially in broader market corrections. Investors should weigh the robust growth narrative against the premium valuation and heightened risk profile.
Market outlook
Short term
< 1 yearPositive
Model confidence8/108 out of 10
Key factors
- Bullish technical indicators (SMA alignment, MACD crossover)
- Quarterly earnings beat and strong bookings growth
- Increasing trading volume supporting momentum
Medium term
1–3 yearsNeutral
Model confidence6/106 out of 10
Key factors
- Significant valuation premium relative to DCF and peers
- Sustained revenue growth and AI‑related market exposure
- High beta and volatility that could amplify market swings
Long term
> 3 yearsNeutral
Model confidence5/105 out of 10
Key factors
- Secular demand for precision automation and medical solutions
- Persistent overvaluation limiting upside potential
- Regulatory and competitive dynamics in the medical technology space
Key metrics
Financial health
Revenue Growth10.40%
Profit Margin5.35%
P/E Ratio108.8
ROE5.16%
ROA4.56%
Debt/Equity22.22
P/B Ratio4.1
Op. Cash Flow$84.0M
Free Cash Flow$87.3M
Industry P/E38.2
Technical analysis
TrendBullish
RSI64.2
Support$120.47
Resistance$165.56
MA 20$137.96
MA 50$127.80
MA 200$122.39
MACDBullish
VolumeIncreasing
Fear & Greed Index89.23
Valuation
Fair Value$52.01
Target Price$171.50
Upside/Downside13.37%
GradeOvervalued
TypeGrowth
Risk assessment
Beta2.05
Volatility57.11%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.